|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09886 DINGDANG HEALTH
Nominal 
0.500 -0.010 (-1.961%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 4,856,806 | 12.190% | 4,329,075 | 3,678,690 | 2,228,563 | 1,275,589 |
| Cost of Sales | (3,346,135) | 16.209% | (2,879,405) | (2,516,379) | (1,462,370) | (805,635) |
| Gross Profit | 1,510,671 | 4.208% | 1,449,670 | 1,162,311 | 766,193 | 469,954 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (356) | -99.986% | (2,506,094) | (912,466) | (757,744) | (150,906) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (48,304) | (33,337) | (2,771) | -- | |
| Share of Results of Asso. & JCEs | (2,445) | -- | 0 | 0 | (256) | (91) | |
| Profit / (Loss) before Taxation | (221,227) | -92.189% | (2,832,147) | (1,581,859) | (900,887) | (265,696) | |
| Taxation | (9,641) | -4.808% | (10,128) | (17,115) | (18,793) | (8,236) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 5,059 | -43.029% | 8,880 | 20,948 | (4,570) | (2,703) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (225,809) | -92.030% | (2,833,395) | (1,578,026) | (924,250) | (276,635) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (24,749) | 168.049% | (9,233) | 13,611 | 2,522 | 3,002 |
| Depreciation & Amortisation | 139,998 | 3.467% | 135,307 | 135,286 | 74,878 | 57,483 |
| Directors' Emoluments | 119,169 | -24.513% | 157,867 | 311,745 | 6,495 | 1,648 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -17.000 | -94.955% | -337.000 | -331.000 | -- | -- |
| DPS (cts) | 0.000 | -- | 0.000 | -- | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.004) | -- | (0.283) | (0.619) | -- | -- |
| NBV per share ($) | 1.519 | -- | 1.629 | -- | -- | -- |
| Remarks: | Real time quote last updated: 27/12/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -84,491 |
| %Change | -24.946% |
| EPS / (LPS) | RMB -0.060 |
| NBV Per Share (¥) | RMB 1.450 |